MET-097i: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (2 countries listed)
Risk Assessment
Not approved by any regulatory authority. Phase 2b completed. Under Pfizer development following $10 billion Metsera acquisition.
The approximately 380-hour half-life means adverse effects cannot be rapidly reversed. Drug levels persist for weeks after discontinuation, complicating management of serious adverse events.
Expected risks include thyroid C-cell tumors (rodent data), pancreatitis, gallbladder disease, and acute kidney injury.
The HALO peptide-oligomer conjugate is a novel molecular format. Immunogenicity and long-term safety of the oligomeric carrier not fully characterized.
⚠️Important Warnings
- •INVESTIGATIONAL COMPOUND: Not approved for human use.
- •Ultra-long half-life (~380 hours): adverse effects persist weeks after discontinuation.
- •GLP-1 agonist class risks apply including thyroid C-cell tumors, pancreatitis, and gallbladder disease.
- •Novel HALO conjugate technology with limited long-term safety data.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Not FDA-approved. Phase 2b VESPER-3 completed. Developed by Metsera, acquired by Pfizer for approximately $10 billion. |
| European Union | Investigational | Not approved. Development status in Europe under Pfizer's global program. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
MET-097i is investigational and not approved by any regulatory authority. It should not be used outside of clinical trials.
Regulatory Status#
| Jurisdiction | Status | Details |
|---|---|---|
| United States | Investigational | Phase 2b completed; Pfizer development |
| European Union | Investigational | Global program under Pfizer |
Ultra-Long Half-Life Risk#
The key unique risk of MET-097i is its approximately 380-hour half-life. While this enables convenient monthly dosing, it also means that if a serious adverse event occurs, drug levels cannot be rapidly reduced. Clinicians and patients should be aware that side effects may persist for several weeks after the last injection.
Novel Technology Considerations#
The HALO platform represents a novel approach to peptide drug delivery. The immunogenicity of the oligomeric carrier, potential for anti-drug antibody formation, and long-term depot effects at injection sites require further characterization in larger, longer trials.
Patients should consider FDA-approved alternatives under medical supervision.
Risk Assessment Context#
MET-097i belongs to the Metabolic category of research peptides. Risk assessment for MET-097i should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.
Risk Categories#
The following risk categories have been identified for MET-097i based on available evidence and regulatory assessments:
Investigational Status#
Not approved by any regulatory authority. Phase 2b completed. Under Pfizer development following $10 billion Metsera acquisition.
Ultra-Long Half-Life Risk#
The approximately 380-hour half-life means adverse effects cannot be rapidly reversed. Drug levels persist for weeks after discontinuation, complicating management of serious adverse events.
GLP-1 Agonist Class Risks#
Expected risks include thyroid C-cell tumors (rodent data), pancreatitis, gallbladder disease, and acute kidney injury.
Novel Conjugate Technology#
The HALO peptide-oligomer conjugate is a novel molecular format. Immunogenicity and long-term safety of the oligomeric carrier not fully characterized.
Regulatory Status by Jurisdiction#
The regulatory and legal status of MET-097i varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.
| Country | Status | Notes |
|---|---|---|
| United States | investigational | Not FDA-approved. Phase 2b VESPER-3 completed. Developed by Metsera, acquired by Pfizer for approximately $10 billion. |
| European Union | investigational | Not approved. Development status in Europe under Pfizer's global program. |
Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.
Important Warnings#
The following warnings apply to MET-097i:
- INVESTIGATIONAL COMPOUND: Not approved for human use.
- Ultra-long half-life (~380 hours): adverse effects persist weeks after discontinuation.
- GLP-1 agonist class risks apply including thyroid C-cell tumors, pancreatitis, and gallbladder disease.
- Novel HALO conjugate technology with limited long-term safety data.
These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.
Related Reading#
Frequently Asked Questions About MET-097i
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.